Degreef H, Dooms-Goossens A
Department of Dermatology, University Hospital, Leuven, Belgium.
Dermatol Clin. 1993 Jan;11(1):155-60.
We cannot as yet fully answer the question of the safety of the new corticosteroids. Budesonide is frequently found to be an allergen now that it is being marketed, and it can certainly serve as a primary sensitizer. For the other new corticosteroids, too, we already had numerous positive tests even before they were marketed. This must be considered cross-sensitivity. We will have to wait to see whether or not they are primary sensitizers. For the pharmaceutical industry, there is one more challenge in the development of new corticosteroids: In addition to finding more effective corticosteroids with the fewest "classic" side effects, the industry will also have to identify the least sensitizing molecules.
我们目前还无法完全回答新型皮质类固醇安全性的问题。布地奈德在上市后经常被发现是一种过敏原，它肯定可以作为主要致敏原。对于其他新型皮质类固醇，甚至在它们上市之前，我们就已经有了大量阳性测试结果。这必须被视为交叉敏感性。我们将不得不等待，看看它们是否是主要致敏原。对于制药行业来说，新型皮质类固醇的研发还有一个挑战：除了找到具有最少“经典”副作用的更有效皮质类固醇外，该行业还必须确定致敏性最低的分子。
